Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.69 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16104891 | 0.91 | DGAT1 (0.74) | DGAT1APPMCHR1DHODH | |
| SCHEMBL27737366 | 0.87 | DGAT1 (0.73) | DGAT1FPR1FPR2MCHR1DHODH | |
| Acetic Acid SCHEMBL2551080 | 0.86 | DGAT1 (0.72) | DGAT1DHODH | |
| SCHEMBL15131446 | 0.85 | DGAT1 (0.84) | DGAT1 | |
| Acetic Acid SCHEMBL15531774 | 0.85 | DGAT1 (0.68) | DGAT1FPR1FPR2 | |
| SCHEMBL30565805 | 0.85 | DGAT1 (0.76) | DGAT1MCHR1DHODH | |
| SCHEMBL29068729 | 0.85 | DGAT1 (0.76) | DGAT1MCHR1DHODH | |
| SCHEMBL29068744 | 0.85 | DGAT1 (0.76) | DGAT1MCHR1DHODH | |
| SCHEMBL180703 | 0.83 | DGAT1 (0.81) | DGAT1FPR1FPR2 | |
| Pradigastat SCHEMBL29358725 | 0.82 | DGAT1 (1.00) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765012-B1 | DGAT1 INHIBITORS FOR USE IN TREATING CONSTIPATION | SERLEVA INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20240293376-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA, INC. | 2024-09-05 | — | — | US | claimed |
| US-11819495-B2 | Compositions and methods for treating severe constipation | ANJI PHARMACEUTICALS INC. (US) | 2023-11-21 | — | — | US | claimed |
| US-20220193044-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA, INC. | 2022-06-23 | — | — | US | claimed |
| US-11224590-B2 | Compositions and methods for treating severe constipation | ANJI PHARMACEUTICALS INC. (US) | 2022-01-18 | — | — | US | claimed |
| EP-3765012-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | Anji Pharmaceuticals Inc. (US) | 2021-01-20 | — | — | EP | claimed |
| US-20190282549-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA, INC. | 2019-09-19 | — | — | US | claimed |
| WO-2019178492-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | ANJI PHARMACEUTICALS INC. (US) | 2019-09-19 | — | — | WO | claimed |
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | claimed |
| US-9061012-B2 | Uses of DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | claimed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | claimed |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | claimed |
| WO-2011123401-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | claimed |
| EP-3765012-B1 | DGAT1 INHIBITORS FOR USE IN TREATING CONSTIPATION | SERLEVA INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000651-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12343334-B2 | Compositions and methods for treating severe constipation | SERLEVA, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2013169648-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DGAT1 INHIBTOR AND A TRIGLYCERIDE LOWERING DRUG | NOVARTIS AG (CH) | 2013-11-14 | — | — | WO | disclosed |
| EP-2552441-A1 | USES OF DGAT1 INHIBITORS | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | US | disclosed |
| WO-2011123401-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000651-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885FPR1 3268/4885FPR2 3786/4885 |
| US-11819495-B2 | Compositions and methods for treating severe constipation | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
| US-11224590-B2 | Compositions and methods for treating severe constipation | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
| US-20130023495-A1 | USES OF DGAT1 INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 3750/4885FPR2 3973/4885 |
| US-20190282549-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
| US-20240293376-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
| US-20220193044-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
| US-12343334-B2 | Compositions and methods for treating severe constipation | DGAT1, DGAT2, LCAT | DGAT1 1/4885FPR1 2365/4885FPR2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.